CapsoVision (CV) Common Equity (2024 - 2025)

CapsoVision's (CV) quarterly Common Equity came in at $13.3 million in Q4 2025, up 110.24% year-on-year from $6.3 million in Q4 2024, and down 35.13% quarter-over-quarter from $20.4 million in Q3 2025.

CapsoVision (CV) Common Equity (2024 - 2025) Analysis & Trends

CapsoVision has disclosed Common Equity across 2 years of filings, most recently posting $13.3 million for Q4 2025.

  • Common Equity for Q4 2025 came in at $13.3 million, up 110.24% year-over-year; the trailing twelve-month figure through Dec 2025 was $13.3 million (up 110.24% YoY), and the FY2025 annual result was $13.3 million, up 110.24% from the prior year.
  • Common Equity came in at $13.3 million for Q4 2025 at CapsoVision, down from $20.4 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $20.4 million in Q3 2025 to a low of -$139.0 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Common Equity (Qtr)
1 Abbott Laboratories 154.42 Bn 147.76 Bn 6.27 Bn 52.70 Bn
2 Stryker 118.12 Bn 115.25 Bn 3.81 Bn 22.98 Bn
3 Medtronic 101.72 Bn 93.55 Bn 5.76 Bn 48.99 Bn
4 Boston Scientific 67.19 Bn 65.98 Bn 3.61 Bn 26.10 Bn
5 Edwards Lifesciences 50.69 Bn 47.02 Bn 1.29 Bn 10.33 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.09 Bn 26.97 Bn 750.30 Mn 2.96 Bn
8 GE HealthCare Technologies 28.08 Bn 26.02 Bn 1.98 Bn 10.68 Bn
9 Steris 19.80 Bn 19.37 Bn 697.10 Mn 7.20 Bn
10 CapsoVision 161.82 Mn 151.71 Mn 1.95 Mn 13.26 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 13.26 Mn
Sep 30, 2025 20.44 Mn
Jun 30, 2025 -138.99 Mn
Dec 31, 2024 -129.51 Mn
Sep 30, 2024 -124.99 Mn
Jun 30, 2024 -119.21 Mn